Improving T cell therapy for melanoma by overcoming resistance mechanisms
Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
['FUNDING_R21'] · UNIV OF ARKANSAS FOR MED SCIS · NIH-10947841
This study is looking at ways to make CAR T cell therapy work better for people with advanced melanoma who haven't responded to other treatments, by figuring out how to help the T cells fight the cancer more effectively in tough conditions.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF ARKANSAS FOR MED SCIS (nih funded) |
| Locations | 1 site (LITTLE ROCK, UNITED STATES) |
| Trial ID | NIH-10947841 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of adoptive T cell therapy, particularly CAR T cells, for patients with metastatic melanoma who have developed resistance to current treatments. The approach involves understanding how the tumor microenvironment affects T cell function and finding ways to engineer T cells that can better survive and function in these challenging conditions. By targeting specific mechanisms that lead to T cell exhaustion, the research aims to improve the overall success of T cell therapies when combined with other treatments. Patients may benefit from more effective therapies that can overcome the limitations of existing options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic melanoma who have not responded to immune checkpoint blockade therapies.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone any form of immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients who currently have limited options due to resistance to existing therapies.
How similar studies have performed: Previous research has shown promise in enhancing T cell therapies for cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
LITTLE ROCK, UNITED STATES
- UNIV OF ARKANSAS FOR MED SCIS — LITTLE ROCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TACKETT, ALAN — UNIV OF ARKANSAS FOR MED SCIS
- Study coordinator: TACKETT, ALAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.